Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA Approves 1st Non-Opioid Pain Drug in 20 Years
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?
Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November,
Biotech Stock Rises After FDA Approves Non-Opioid Painkiller
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug Administration (FDA) approved the biotech's new non-opioid painkiller, Journavx. In a statement to the press,
FDA approves Vertex's first-in-class non-opioid analgesic for acute pain
Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) Journavx (suzetrigine) 50 milligram oral tablets. This new drug is a non-opioid analgesic,
21h
on MSN
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...
3d
Biotech Stocks Facing FDA Decision In February 2025
February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...
6d
on MSN
Atara to cut 50% of workforce amid FDA woes
Atara Biotherapeutics (NASDAQ:ATRA) has announced plans to cut around 50% of its workforce, just a little over a week after it said the FDA had declined to approve its immunotherapy Ebvallo. The ...
10d
on MSN
2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher
Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...
2d
Buy Rating for Vertex Pharmaceuticals: FDA Approval of Journavx Boosts Market Potential and Stock Price Target
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...
3d
on MSN
Axsome gets FDA approval for Symbravo for migraine
Axsome Therapeutics (NASDAQ:AXSM) has received FDA approval for its drug Symbravo for the acute treatment of migraine with or ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback